Luye Pharma Group (HKSE:02186) Total Current Assets : HK$11,707 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Luye Pharma Group Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Luye Pharma Group's total current assets for the quarter that ended in Dec. 2023 was HK$11,707 Mil.

Luye Pharma Group Total Current Assets Historical Data

The historical data trend for Luye Pharma Group's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luye Pharma Group Total Current Assets Chart

Luye Pharma Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

10,595.57

11,819.29

12,730.38

12,044.68

11,707.02

Luye Pharma Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Current Assets	Get a 7-Day Free Trial															12,730.38	12,033.92	12,044.68	14,338.41	11,707.02

Luye Pharma Group Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Luye Pharma Group's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	9321.475	+	2830.325	+	905.499	+	-1350.275
	=	11,707

Luye Pharma Group's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	9321.475	+	2830.325	+	905.499	+	-1350.275
	=	11,707

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Luye Pharma Group (HKSE:02186) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Luye Pharma Group's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	9321.475	-	13084.025	+	0.75 * 2163.359	+	0.5 * 905.499
=	-1,687

Luye Pharma Group Total Current Assets Related Terms

Thank you for viewing the detailed overview of Luye Pharma Group's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Luye Pharma Group (HKSE:02186) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luye Pharma Group Ltd (HKSE:02186) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

LYPHF:USA LUP:Germany LUP:Germany

Address

No. 15 Chuang Ye Road, High-tech Industrial Development Zone, Shandong, Yantai, CHN, 264003

Website

https://www.luye.cn

Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on developing, producing, and selling pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for global use in Asia, Europe, and the United States.

Executives

Ubs Group Ag	2201 Interest of corporation controlled by you
Liu Dianbo	2301 Trustee
Luye Life Sciences Group Ltd	2201 Interest of corporation controlled by you
Luye Pharma Holdings Ltd.	2201 Interest of corporation controlled by you
Nelumbo Investments Limited	2201 Interest of corporation controlled by you
Shorea Lbg	2201 Interest of corporation controlled by you
Luye Pharmaceutical Investment Co., Ltd.	2101 Beneficial owner
Ginkgo (ptc) Limited	2301 Trustee
Luye Pharmaceutical International Co., Ltd.	2201 Interest of corporation controlled by you
Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Hillhouse Nev Holdings Limited	2101 Beneficial owner
Hillhouse Investment Management, Ltd.	2102 Investment manager
Hillhouse Fund V, L.p.	2201 Interest of corporation controlled by you
Xin Ye Sheng Wu Yi Yao Kong Gu You Xian Gong Si
Yang Yu Fen

Luye Pharma Group (HKSE:02186) Headlines

No Headlines